TN2016000522A1 - Intermittent dosing of mdm2 inhibitor - Google Patents

Intermittent dosing of mdm2 inhibitor

Info

Publication number
TN2016000522A1
TN2016000522A1 TN2016000522A TN2016000522A TN2016000522A1 TN 2016000522 A1 TN2016000522 A1 TN 2016000522A1 TN 2016000522 A TN2016000522 A TN 2016000522A TN 2016000522 A TN2016000522 A TN 2016000522A TN 2016000522 A1 TN2016000522 A1 TN 2016000522A1
Authority
TN
Tunisia
Prior art keywords
mdm2 inhibitor
mdm2i
intermittent dosing
mdm2
treatment
Prior art date
Application number
TN2016000522A
Other languages
English (en)
Inventor
Stephane Ferretti
Sebastien Jeay
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2016000522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2016000522A1 publication Critical patent/TN2016000522A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2016000522A 2014-06-26 2015-06-25 Intermittent dosing of mdm2 inhibitor TN2016000522A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017406P 2014-06-26 2014-06-26
PCT/IB2015/054792 WO2015198266A1 (en) 2014-06-26 2015-06-25 Intermittent dosing of mdm2 inhibitor

Publications (1)

Publication Number Publication Date
TN2016000522A1 true TN2016000522A1 (en) 2018-04-04

Family

ID=53510950

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2016000522A TN2016000522A1 (en) 2014-06-26 2015-06-25 Intermittent dosing of mdm2 inhibitor

Country Status (18)

Country Link
US (6) US20170196866A1 (enExample)
EP (1) EP3160463B1 (enExample)
JP (1) JP6728072B2 (enExample)
KR (3) KR102462177B1 (enExample)
CN (2) CN106456635A (enExample)
AU (1) AU2015278765B2 (enExample)
BR (1) BR112016029750A2 (enExample)
CA (1) CA2953079C (enExample)
CL (1) CL2016003295A1 (enExample)
ES (1) ES2856210T3 (enExample)
IL (1) IL249138B (enExample)
MX (1) MX2016017075A (enExample)
PH (1) PH12016502556A1 (enExample)
RU (1) RU2695228C2 (enExample)
SG (1) SG11201609853VA (enExample)
TN (1) TN2016000522A1 (enExample)
TW (1) TW201613576A (enExample)
WO (1) WO2015198266A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
RU2016111360A (ru) 2010-08-13 2018-11-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP6890659B2 (ja) * 2016-11-15 2021-06-18 ノバルティス アーゲー ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン
MX390667B (es) * 2017-03-31 2025-03-21 Novartis Ag Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
JP7358372B2 (ja) * 2018-03-12 2023-10-10 羅欣薬業（上海）有限公司 イミダゾピロロン化合物及びその使用
US20210363254A1 (en) 2018-03-20 2021-11-25 Novartis Ag Pharmaceutical combinations
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
JP2021525795A (ja) * 2018-05-25 2021-09-27 カルトス セラピューティクス，インコーポレイテッド 骨髄増殖性腫瘍を治療する方法
CN113194952A (zh) * 2018-12-20 2021-07-30 诺华股份有限公司 Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
US20220331318A1 (en) 2019-09-16 2022-10-20 Novartis Ag Use of an mdm2 inhibitor for the treatment of myelofibrosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
MX2007010272A (es) 2005-02-22 2008-03-12 Univ Michigan Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN102770182B (zh) * 2009-12-22 2014-10-29 诺华股份有限公司 被取代的异喹啉酮类和喹唑酮类
PL2361667T3 (pl) 2010-02-25 2015-07-31 General Electric Technology Gmbh Płuczka wodna i sposób oczyszczania gazu procesowego
CN103298818B (zh) 2010-11-12 2016-06-29 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
MX2013006739A (es) * 2010-12-16 2013-07-17 Roche Glycart Ag Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
RS55974B1 (sr) 2011-08-11 2017-09-29 Estetra Sprl Upotreba estetrola kao kontraceptivnog sredstva u hitnim slučajevima
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US8815926B2 (en) * 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
HUE045880T2 (hu) * 2012-07-31 2020-01-28 Novartis Ag A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
JP6297695B2 (ja) 2013-12-05 2018-03-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 急性骨髄性白血病（ａｍｌ）のための新規併用治療
CA2931073C (en) 2013-12-23 2021-10-26 Novartis Ag Pharmaceutical combinations
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2016127135A1 (en) 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons
EP3284466A4 (en) 2015-04-13 2018-12-05 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
TWI804010B (zh) 2015-08-03 2023-06-01 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
RU2020142739A (ru) 2015-08-28 2021-01-15 Новартис Аг Ингибиторы mdm2 и их комбинации
JP6890659B2 (ja) 2016-11-15 2021-06-18 ノバルティス アーゲー ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン
KR20190079680A (ko) 2016-11-22 2019-07-05 노파르티스 아게 이미다조피롤리디논 유도체 및 이의 중간체의 화학적 제조 방법
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
MX390667B (es) 2017-03-31 2025-03-21 Novartis Ag Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
EP3694518A1 (en) 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
US20210363254A1 (en) 2018-03-20 2021-11-25 Novartis Ag Pharmaceutical combinations
US12115151B2 (en) 2018-10-30 2024-10-15 Dana-Farber Cancer Institute, Inc. Method of treatment of p53 WT tumors
CN113194952A (zh) 2018-12-20 2021-07-30 诺华股份有限公司 Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
WO2020202052A1 (en) 2019-04-04 2020-10-08 Novartis Ag Siremadlin succinate

Also Published As

Publication number Publication date
US20210000824A1 (en) 2021-01-07
AU2015278765A1 (en) 2017-01-19
CA2953079A1 (en) 2015-12-30
PH12016502556A1 (en) 2017-04-17
BR112016029750A2 (pt) 2017-08-22
KR20170017932A (ko) 2017-02-15
AU2015278765B2 (en) 2018-08-16
CA2953079C (en) 2023-05-02
JP6728072B2 (ja) 2020-07-22
CN115569197A (zh) 2023-01-06
KR102462177B1 (ko) 2022-11-04
JP2017519019A (ja) 2017-07-13
TW201613576A (en) 2016-04-16
US11419870B2 (en) 2022-08-23
RU2017102319A3 (enExample) 2019-02-12
KR20240110659A (ko) 2024-07-15
US20220233530A9 (en) 2022-07-28
US20230092181A1 (en) 2023-03-23
MX2016017075A (es) 2017-05-03
IL249138B (en) 2020-09-30
SG11201609853VA (en) 2017-01-27
CL2016003295A1 (es) 2017-07-28
RU2017102319A (ru) 2018-07-26
CN106456635A (zh) 2017-02-22
IL249138A0 (en) 2017-01-31
EP3160463A1 (en) 2017-05-03
EP3160463B1 (en) 2020-10-21
US20170196866A1 (en) 2017-07-13
RU2695228C2 (ru) 2019-07-22
ES2856210T3 (es) 2021-09-27
US20240261284A1 (en) 2024-08-08
US20180110779A1 (en) 2018-04-26
US20190209561A1 (en) 2019-07-11
KR20220151027A (ko) 2022-11-11
WO2015198266A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
PH12016502556A1 (en) Intermittent dosing of mdm2 inhibitor
MX2017010858A (es) Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CA2971109C (en) SITE-SPECIFIC DOSAGE OF A BTK INHIBITOR
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502352A1 (en) Pharmaceutical composition
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
IN2013MU03428A (enExample)
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
PH12016502527A1 (en) Stabilized desmopressin
IN2013MU01226A (enExample)
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
IN2013MU03069A (enExample)